Remove Heart Rhythm Remove Hospital Remove Quality of Life
article thumbnail

Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment

DAIC

During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). director of electrophysiology, Mount Sinai Fuster Heart Hospital , New York.

article thumbnail

Atrial fibrillation and COVID-19: an analysis of the ambulatory database

Frontiers in Cardiovascular Medicine

Atrial fibrillation (AF) is the most common heart rhythm disorder in clinical practice. It worsens the quality of life of patients, leads to an increase in the mortality rate because of its association with a high risk of thromboembolic complications. However, most research in this area has focused on hospital patients.

article thumbnail

News from EHRA 2024: International Experts Agree on Standards for Catheter Ablation of Atrial Fibrillation

DAIC

Four heart rhythm organizations from around the globe developed the statement. It is also published in Heart Rhythm , the official journal of the HRS, Journal of Arrhythmia , the official journal of the APHRS, and Journal of Interventional Cardiac Electrophysiology , the official journal of the LAHRS.

article thumbnail

CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim

DAIC

Dr. JoAnn Lindenfeld of Vanderbilt University presented analysis showing that patients with Barostim + GDMT had sustained and significant improvements in quality-of-life scores (MLWHF and EQ-5D) and many subdomains of these scores (e.g., See more details at TCTMD. versus patients on GDMT alone.

article thumbnail

Ninerafaxstat Well-Tolerated and Safe for Nonobstructive Hypertrophic Cardiomyopathy

DAIC

Maron, MD “Our findings provide enthusiasm that a novel drug therapy with ninerafaxstat may provide nonobstructive HCM patients an opportunity to achieve a better quality of life by decreasing symptom burden and improving exercise capacity,” said Martin S. The safety and tolerability of the drug in this phase 2 trial was excellent.

article thumbnail

HRS 2024: Innovation Meets Reality

DAIC

In electrophysiology, innovation is king, but it is often incremental, and it almost always lacks rationale, comprehensive clinical documentation and relevance for hospitals that try to balance the increasing costs of new technology with increasing demand and reimbursement that just can’t keep pace.

article thumbnail

Published Research

Society of Thoracic Surgeons - Research

Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)